Payal Jain

Payal Jain is a research scientist responsible for basic and translational research to identify targeted therapeutics for treating pediatric low-grade gliomas (PLGG), with a focus on elucidating molecular mechanisms of response to therapy and subsequent resistance. She also seeks to understand the oncogenic role of both gene fusion partners in distinct PLGG gene fusions, focusing on a mechanistic understanding that would eventually lead to testing novel therapeutics, including small molecule inhibitors and subsequent resistance in PLGG patients. Payal uses relevant in vitro assays, cellular model systems and in vivo mouse preclinical models to answer scientific questions. She is also involved in writing scientific manuscripts and building a standard workflow to streamline our research efforts into a high-throughput process utilizing large-scale sequencing data generated by the D³b center.

Payal joined CHOP in August of 2016. She earned a B.Tech in Biotechnology from Amity University in India before completing a MA in Biotechnology from Columbia University in New York, NY. Payal completed a PhD in Biomedical Sciences at the University of Pennsylvania.

Clinical Research